Editorial Board member, Bernardo Rapoport discusses neoadjuvant breast cancer at the ASCO 2019 annual meeting. Considering data presented at the meeting he also reviews the unmet needs, what factors influence treatment in this population and how to overcome current treatment challenges.
1. What are the major unmet needs in the neoadjuvant treatment of breast cancer? (0:04)
2. What factors influence the decision to give neoadjuvant treatment? (2:20)
3. What are the challenges of assessing response to neoadjuvant therapies and how can these be overcome? (3:06)
4. Could you tell us about the latest data on trastuzumab emtansine in the neoadjuvant treatment of HER2-positive breast cancer? (4:08)
5. What presentations on neoadjuvant breast cancer are you most interested in at this year’s meeting? (5:59)
Speaker disclosure: Bernardo Rapoport has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!